Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0359920110300010041
Korean Journal of Nephrology
2011 Volume.30 No. 1 p.41 ~ p.47
Hemoglobin Variability Associated with Different Erythropoiesis Stimulating Agents in Hemodialysis Patients
Park Su-Kyoung

Hwang Kyu-Sig
Park Joon-Sung
Lee Chang-Hwa
Kang Chong-Myung
Kim Gheun-Ho
Abstract
Purpose: This study was undertaken to examine whether differences exist in the hemoglobin variability according to the types of erythropoiesis stimulating agent (ESA) in hemodialysis (HD) patients.

Methods: Clinical data were retrospectively analyzed from 72 patients on maintenance hemodialysis who were using darbepoetin alfa (n=27), epoetin beta (n=27), and epoetin alpha (n=18). As parameters of hemoglobin variability, hemoglobin cycling, the variance of hemoglobin and the SD/mean of hemoglobin were analyzed. Hemoglobin cycling was defined as the presence of cycles with an amplitude >1.5 g/dL and lasting more than 2 months.

Results: Hemoglobin cycling was present in 53 (73.6%) out of 72 HD patients. Hemoglobin cycling in patients receiving darbepoetin alfa had greater frequency (1.63¡¾0.93 vs. 1.00¡¾0.88 times/year, p<0.05), amplitude (2.88¡¾1.48 vs. 1.88¡¾1.60 g/dL, p<0.05), and velocity (1.21¡¾0.74 vs. 0.73¡¾0.66 g/dL/month, p<0.05) than that in patients receiving epoetin beta. The variance of hemoglobin in patients receiving epoetin beta (0.79¡¾0.53 g/dL) was smaller than that in patients receiving darbepoetin alfa (1.29¡¾0.70 g/dL, p<0.05) and epoetin alfa (1.08¡¾0.52 g/dL, p<0.05). Also, the ratio of SD/mean of hemoglobin in patients receiving epoetin beta (8.20¡¾2.59%) was lower than that in patients receiving darbepoetin alfa (10.81¡¾2.10%, p<0.05) and epoetin alfa (10.30¡¾2.10%, p<0.05).

Conslusion: Hemoglobin variability is differential according to various ESAs, and it may be less with epoetin beta compared with darbepoetin alpha and epoetin alpha.
KEYWORD
Anemia, Hematinics, Renal dialysis, Hemoglobin
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø